Development of a diagnostic biomarker panel for early-stage lung adenocarcinoma using serum-derived small RNAs

OBJECTIVE: Circulating small RNAs, such as microRNAs (miRNAs) and transfer RNA fragments (tRFs), reportedly reflect the physiological and pathological conditions in various diseases. Herein, we aimed to identify circulating small RNAs for the early diagnosis of lung adenocarcinoma. METHODS: This study included 40 healthy controls and 43 patients with lung adenocarcinoma. We analyzed their serum using small RNA sequencing and identified differentially expressed small RNAs between healthy controls and patients with lung adenocarcinoma. We verified the expression profiles of these small RNAs in 29 patients with lung adenocarcinoma and 27 healthy controls. Finally, we evaluated our current results by performing machine learning-based analysis. RESULTS: The expressions of two mature miRNAs (miR-193a-5p, miR-423-5p), one miRNA isoform (isomiR) (miR-423-5p(21nt)), and two tRFs (tRF-Gly(CCC)(29nt), tRF-Gly(CCC)(30nt)) were significantly elevated in patients with lung adenocarcinoma than in healthy controls. Moreover, the expressions of one miRNA (miR-20a-5p) and five tRFs (tRF-iMet(CAT)(31nt), tRF-Lys(CTT), tRF-iMet(CAT)(30nt), tRF-iMet(CAT)(29nt), tRF-Val(AAC)) were significantly decreased in patients with lung adenocarcinoma than in healthy controls (area under the curve [AUC] values = 0.71 to 0.85, respectively). Furthermore, a combination of six small RNAs (miR-193a-5p, miR-423-5p(21nt), miR-20a-5p, tRF-Gly(CCC)(29nt), tRF-iMet(CAT)(29nt), and tRF-Val(AAC)) was useful for developing a biomarker panel for the early diagnosis of lung adenocarcinoma. Discovery screening revealed that the panel demonstrated a sensitivity of 0.954 and a specificity of 0.925 (AUC = 0.974), whereas the validation data demonstrated a sensitivity of 0.690 and a specificity of 0.926 (AUC = 0.924). CONCLUSION: Serum-derived small RNAs are associated with the status of patients with lung adenocarcinoma, and evaluating small RNAs in serum is a promising non-invasive approach for diagnosing lung adenocarcinoma at an early stage.

Authors

Institutions

Publication Details

Journal
PLoS ONE
Published
2026-11-16
DOI
https://doi.org/10.1371/journal.pone.0362879
Primary Topic
MicroRNA in disease regulation
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Development of a diagnostic biomarker panel for early-stage lung adenocarcinoma using serum-derived small RNAs

Yasuhiro Tsutani, Daisuke Ueda, Junko Tanaka, Yukie Nishiyama et al.
PLoS ONE
MicroRNA in disease regulation
article

Development of a diagnostic biomarker panel for early-stage lung adenocarcinoma using serum-derived small RNAs

Yasuhiro Tsutani, Daisuke Ueda, Junko Tanaka, Yukie Nishiyama, Yumiko Koi, Tomoyuki Akita, Hidetoshi Tahara, Yuta Ibuki, Yoshihiro Miyata, Ryou‐u Takahashi, Morihito Okada
article en

Abstract

OBJECTIVE: Circulating small RNAs, such as microRNAs (miRNAs) and transfer RNA fragments (tRFs), reportedly reflect the physiological and pathological conditions in various diseases. Herein, we aimed to identify circulating small RNAs for the early diagnosis of lung adenocarcinoma. METHODS: This study included 40 healthy controls and 43 patients with lung adenocarcinoma. We analyzed their serum using small RNA sequencing and identified differentially expressed small RNAs between healthy controls and patients with lung adenocarcinoma. We verified the expression profiles of these small RNAs in 29 patients with lung adenocarcinoma and 27 healthy controls. Finally, we evaluated our current results by performing machine learning-based analysis. RESULTS: The expressions of two mature miRNAs (miR-193a-5p, miR-423-5p), one miRNA isoform (isomiR) (miR-423-5p(21nt)), and two tRFs (tRF-Gly(CCC)(29nt), tRF-Gly(CCC)(30nt)) were significantly elevated in patients with lung adenocarcinoma than in healthy controls. Moreover, the expressions of one miRNA (miR-20a-5p) and five tRFs (tRF-iMet(CAT)(31nt), tRF-Lys(CTT), tRF-iMet(CAT)(30nt), tRF-iMet(CAT)(29nt), tRF-Val(AAC)) were significantly decreased in patients with lung adenocarcinoma than in healthy controls (area under the curve [AUC] values = 0.71 to 0.85, respectively). Furthermore, a combination of six small RNAs (miR-193a-5p, miR-423-5p(21nt), miR-20a-5p, tRF-Gly(CCC)(29nt), tRF-iMet(CAT)(29nt), and tRF-Val(AAC)) was useful for developing a biomarker panel for the early diagnosis of lung adenocarcinoma. Discovery screening revealed that the panel demonstrated a sensitivity of 0.954 and a specificity of 0.925 (AUC = 0.974), whereas the validation data demonstrated a sensitivity of 0.690 and a specificity of 0.926 (AUC = 0.924). CONCLUSION: Serum-derived small RNAs are associated with the status of patients with lung adenocarcinoma, and evaluating small RNAs in serum is a promising non-invasive approach for diagnosing lung adenocarcinoma at an early stage.

PLoS ONEVol. 21(11)
Hiroshima University (JP), Research Institute for Radiation Biology and Medicine, Hiroshima University (JP)
Japan Agency for Medical Research and Development, New Energy and Industrial Technology Development Organization
Good health and well-being
MicroRNA in disease regulation
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon